TY - JOUR
T1 - Nonallergic Rhinitis, Allergic Rhinitis, and Immunotherapy
T2 - Advances in the Last Decade
AU - Ponda, Punita
AU - Carr, Tara
AU - Rank, Matthew A.
AU - Bousquet, Jean
N1 - Funding Information:
Conflicts of interest: P. Ponda is a site principal investigator on clinical trials with GlaxoSmithKline (GSK), Regeneron, Nestle, Allakos, Novartis, and Revolo Therapeutics. T. Carr has served in an advisory or consulting role for Genentech, AstraZeneca, and GSK, and receives royalties for author/reviewer services from UpToDate. M. A. Rank has no conflicts of interest to report. J. Bousquet reports personal fees from Cipla, Menarini, Mylan, Novartis, Purina, Sanofi-Aventis, Teva, and Uriach and is shareholder of KYomed Innov and MASK-air-SAS. The authors did not receive any funding for this study.
Publisher Copyright:
© 2022 American Academy of Allergy, Asthma & Immunology
PY - 2023/1
Y1 - 2023/1
N2 - Chronic rhinitis encompassing both allergic and nonallergic rhinitis affects a significant portion of the population worldwide, having a great impact on patient quality of life, and associated comorbid conditions, with an important societal economic burden. Allergists are often the first to evaluate and treat allergic and nonallergic rhinitis, addressing the individual triggers of the disease as well as the patient-specific responses to these triggers. This review focuses on the advances that have been made in the diagnosis, management, and treatment of nonallergic and allergic rhinitis over the past 10 years, including specific allergen immunotherapy, care pathways, and digital health.
AB - Chronic rhinitis encompassing both allergic and nonallergic rhinitis affects a significant portion of the population worldwide, having a great impact on patient quality of life, and associated comorbid conditions, with an important societal economic burden. Allergists are often the first to evaluate and treat allergic and nonallergic rhinitis, addressing the individual triggers of the disease as well as the patient-specific responses to these triggers. This review focuses on the advances that have been made in the diagnosis, management, and treatment of nonallergic and allergic rhinitis over the past 10 years, including specific allergen immunotherapy, care pathways, and digital health.
KW - Allergen immunotherapy
KW - Allergic rhinitis
KW - Care pathway
KW - Digital health
KW - Immunotherapy
KW - Mobile Airways Sentinel NetworK
KW - Nonallergic rhinitis
UR - http://www.scopus.com/inward/record.url?scp=85139738378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139738378&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2022.09.010
DO - 10.1016/j.jaip.2022.09.010
M3 - Article
C2 - 36152989
AN - SCOPUS:85139738378
SN - 2213-2198
VL - 11
SP - 35
EP - 42
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 1
ER -